What Is Adial Pharmaceuticals, Inc (ADIL) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Adial Pharmaceuticals, Inc's intrinsic value is estimated at a composite $2.87, showing conflicting signals at the current price of $2.69. While the average implied return is +6.9%, model disagreement is elevated with a gap of +189.4% between the most bullish and bearish estimates. The most optimistic model, Sentiment SOTP, places fair value at $5.42 (+101.8%), while ML-RIV — the most conservative — estimates $0.33 (-87.6%). This +189.4% gap reflects genuine analytical uncertainty about Adial Pharmaceuticals, Inc's intrinsic worth.
What Do the Models Say About ADIL?
7 of 13 models are currently active for ADIL. Of these, 3 models suggest upside while 4 models suggest overvaluation. The Bayesian DCF estimates ADIL's intrinsic value at $1.86, implying -30.7% downside from the current price. See which stocks rank higher →
How Does ADIL Rank in Biotechnology?
Among 76 Biotechnology stocks, ADIL ranks #55 by Quality of Company score. CirclFi's QOC score of 4.4/10 evaluates 32 fundamental signals. A score of 4.4 reflects mixed fundamentals.
See all Most Undervalued Biotechnology Stocks →
The Biotechnology sector introduces analytical considerations specific to biotech businesses. For Adial Pharmaceuticals, Inc, metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.
Is ADIL a Value Trap?
CirclFi's Value Trap algorithm assigns ADIL a score of 39/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Adial Pharmaceuticals, Inc. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Adial Pharmaceuticals, Inc scores 4.4 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +189.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ADIL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ADIL's 7 active models, average confidence is 27%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad